his.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Effects of Digitoxin and Pembrolizumab treatment on HepG2 cancer cell line
Högskolan i Skövde, Institutionen för hälsa och lärande.
2019 (Engelska)Självständigt arbete på grundnivå (kandidatexamen), 20 poäng / 30 hpStudentuppsats (Examensarbete)
Abstract [en]

Hepatocellular carcinoma (HCC) is the main disease affecting the liver and widely extended over the population, with a prevalence that has increased over the years. Several studies have shown the effect of digitoxin (a cardiac glycoside) and pembrolizumab (an immunotherapy antibody) in reducing the viability of cancer cells by promoting apoptosis and increasing the action of T-cells against them, respectively. In this project, a study was conducted in order to assess the effect of these two drugs on the HepG2 cancer cell line after 24, 48, and 72h of treatment. Different concentrations of the drugs were tested to identify the existence of any significant difference in the cell’s viability with 1, 5, 10, 25 and 100 nM of digitoxin and 0.5, 2, 10 and 50 mg/L of pembrolizumab and their combination. An MTS assay was performed as well as an Amplex-Red assay in order to measure the cell viability and the ROS (reactive oxygen species) levels. Finally, the expression of PD-1, PD-L1, and PD-L2, important genes for the tumor progression, was measured performing a RT-q-PCR. The results showed that certain concentrations of the drugs promoted a decrease in the cell viability, indeed, showing synergetic effects when combined. Moreover, the expression of the genes was confirmed, obtaining a significant variability depending on the treatment. Finally, ROS levels decreased after the treatment at specific concentrations.

Ort, förlag, år, upplaga, sidor
2019. , s. 42
Nyckelord [en]
Hepatocellular carcinoma, HepG2, Digitoxin, Pembrolizumab, cell viability, PD-1, PD-L1, PD-L2
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:his:diva-17745OAI: oai:DiVA.org:his-17745DiVA, id: diva2:1356591
Utbildningsprogram
Biomedicinprogrammet
Handledare
Examinatorer
Tillgänglig från: 2019-10-07 Skapad: 2019-10-01 Senast uppdaterad: 2019-10-07Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Sök vidare i DiVA

Av författaren/redaktören
Lozano Madueño, Cristina
Av organisationen
Institutionen för hälsa och lärande
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 45 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf